canada clinical guidance

Visible & non-visible haematuria (assessment + referral)

A Canadian clinical summary of visible & non-visible haematuria (assessment + referral), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. British Columbia is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.

British Columbia source: bounded use

Workup of Microscopic Hematuria supplies a Canadian implementation example for this summary. It must not be presented as the rule outside British Columbia.
sources for this section:BC hematuria

Source-attributed clinical priorities

  • Confirm blood with urinalysis and distinguish glomerular, infectious, stone, traumatic and urologic cancer features.
  • Do not dismiss hematuria solely because the patient takes anticoagulants; evaluate according to malignancy and renal risk.
  • Use the local urology and nephrology referral pathways, escalating clots with retention, sepsis or acute kidney injury.
  • Repeat a properly collected urine sample and assess microscopy and protein when glomerular disease is possible.
sources for this section:BC hematuria

Practical assessment and management workflow

1
Confirm visible versus microscopic blood and ask about infection, stones, exercise, menstruation, trauma and anticoagulants.
2
Check blood pressure, kidney function, urinalysis and culture and assess malignancy risk.
3
Use risk-directed imaging and cystoscopy through the Canadian urology pathway.
4
Track completion and refer nephrology when proteinuria, casts or impaired kidney function suggests renal disease.
sources for this section:BC hematuria

Safety, red flags and urgent escalation

  • Clot retention, anuria, sepsis or unstable bleeding needs emergency urologic care.
  • Do not dismiss hematuria because the patient is anticoagulated.
  • Persistent visible hematuria requires evaluation even after an apparent UTI resolves.
sources for this section:BC hematuria

Confirm the local pathway before acting

British Columbia is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:BC hematuria

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:BC hematuria

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Government of British ColumbiaWorkup of Microscopic Hematuriaaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.